Skip to main content
Top
Published in: Irish Journal of Medical Science (1971 -) 2/2014

01-06-2014 | Original Article

Promoter hypermethylation-mediated down-regulation of RUNX3 gene in human brain tumors

Authors: C. B. Avci, Y. Dodurga, S. Y. Susluer, Z. O. D. Sıgva, M. Yucebas, H. O. Caglar, T. Akalin, T. Dalbasti, N. Oktar, C. Gunduz

Published in: Irish Journal of Medical Science (1971 -) | Issue 2/2014

Login to get access

Abstract

Background

The Runx family proteins, including RUNX3, are tissue-restricted transcription factors and play role in neuronal development and tumorigenesis. RUNX3 has an important role in glioblastoma (GBM) tumorigenesis because of its promoter hypermethylation.

Aim

We aimed to evaluate the methylation-mediated expression regulation of RUNX3 gene in brain tumors.

Patients and methods

Cases of meningiomas WHO grade III (3), anaplastic astrocytomas (3), diffuse astrocytoma (3), and GBM (12) were recruited into this study. Real-time quantitative PCR was performed for analyses of DNA promoter methylation and analyses of methylation-mediated expression status of RUNX3 gene was performed by real-time quantitative RT-PCR.

Results

There was no significant difference between methylated and unmethylated quantitative ratio of RUNX3 gene promoter region and also no significant difference in relative ratio of RUNX3 gene expression in brain tumor groups. Methylated and unmethylated ratio in anaplastic astrocytoma, diffuse astrocytoma, GBM, meningioma (WHO grade III) and in all groups were; 1.44, 1.09, 1.51, 1.52 and 1.43, respectively. One allele was found methylated necessarily. No methylation was detected in one case of GBM group and one case of anaplastic astrocytoma group. There was no unmethylated promoter in one of the GBM cases. There were significant differences between relative ratio of RUNX3 gene expression and methylated/unmethylated ratio rates for all cases (p = 0.001) and GBM groups (p = 0.041).

Conclusion

This study overemphasized the RUNX3 gene importance in brain tumors, due to the existence of at least one methylated allele.
Literature
1.
go back to reference Hill CI, Nixon CS, Ruehmeier JL, Wolf LM (2002) Brain tumors. Phys Ther 82(5):496–502PubMed Hill CI, Nixon CS, Ruehmeier JL, Wolf LM (2002) Brain tumors. Phys Ther 82(5):496–502PubMed
4.
go back to reference Kamachi Y, Ogawa E, Asano M et al (1990) Purification of a mouse nuclear factor that binds to both the A and B cores of the polyomavirus enhancer. J Virol 64(10):4808–4819PubMedCentralPubMed Kamachi Y, Ogawa E, Asano M et al (1990) Purification of a mouse nuclear factor that binds to both the A and B cores of the polyomavirus enhancer. J Virol 64(10):4808–4819PubMedCentralPubMed
6.
go back to reference Wang Q, Stacy T, Binder M et al (1996) Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci USA 93(8):3444–3449PubMedCentralPubMedCrossRef Wang Q, Stacy T, Binder M et al (1996) Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci USA 93(8):3444–3449PubMedCentralPubMedCrossRef
7.
go back to reference North T, Gu TL, Stacy T et al (1999) Cbfa2 is required for the formation of intra-aortic hematopoietic clusters. Development 126(11):2563–2575PubMed North T, Gu TL, Stacy T et al (1999) Cbfa2 is required for the formation of intra-aortic hematopoietic clusters. Development 126(11):2563–2575PubMed
11.
12.
go back to reference Lam K, Zhang DE (2012) RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis. Front Biosci 17:1120–1139. doi:3977 CrossRef Lam K, Zhang DE (2012) RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis. Front Biosci 17:1120–1139. doi:3977 CrossRef
13.
go back to reference Mangan JK, Speck NA (2011) RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making. Crit Rev Oncog 16(1–2):77–91PubMedCentralPubMedCrossRef Mangan JK, Speck NA (2011) RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making. Crit Rev Oncog 16(1–2):77–91PubMedCentralPubMedCrossRef
15.
18.
go back to reference Miyagawa K, Sakakura C, Nakashima S et al (2006) Down-regulation of RUNX1, RUNX3 and CBFbeta in hepatocellular carcinomas in an early stage of hepatocarcinogenesis. Anticancer Res 26(5B):3633–3643PubMed Miyagawa K, Sakakura C, Nakashima S et al (2006) Down-regulation of RUNX1, RUNX3 and CBFbeta in hepatocellular carcinomas in an early stage of hepatocarcinogenesis. Anticancer Res 26(5B):3633–3643PubMed
19.
go back to reference Sakakura C, Hagiwara A, Miyagawa K et al (2005) Frequent downregulation of the runt domain transcription factors RUNX1, RUNX3 and their cofactor CBFB in gastric cancer. Int J Cancer 113(2):221–228. doi:10.1002/ijc.20551 PubMedCrossRef Sakakura C, Hagiwara A, Miyagawa K et al (2005) Frequent downregulation of the runt domain transcription factors RUNX1, RUNX3 and their cofactor CBFB in gastric cancer. Int J Cancer 113(2):221–228. doi:10.​1002/​ijc.​20551 PubMedCrossRef
21.
go back to reference Li QL, Kim HR, Kim WJ et al (2004) Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer. Biochem Biophys Res Commun 314(1):223–228. doi:S0006291X03026706 PubMedCrossRef Li QL, Kim HR, Kim WJ et al (2004) Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer. Biochem Biophys Res Commun 314(1):223–228. doi:S0006291X0302670​6 PubMedCrossRef
31.
go back to reference Moley JF, Brother MB, Fong CT et al (1992) Consistent association of 1p loss of heterozygosity with pheochromocytomas from patients with multiple endocrine neoplasia type 2 syndromes. Cancer Res 52(4):770–774PubMed Moley JF, Brother MB, Fong CT et al (1992) Consistent association of 1p loss of heterozygosity with pheochromocytomas from patients with multiple endocrine neoplasia type 2 syndromes. Cancer Res 52(4):770–774PubMed
32.
go back to reference Bièche I, Champème MH, Matifas F et al (1993) Two distinct regions involved in 1p deletion in human primary breast cancer. Cancer Res 53(9):1990–1994PubMed Bièche I, Champème MH, Matifas F et al (1993) Two distinct regions involved in 1p deletion in human primary breast cancer. Cancer Res 53(9):1990–1994PubMed
33.
go back to reference Brodeur GM, Green AA, Hayes FA et al (1981) Cytogenetic features of human neuroblastomas and cell lines. Cancer Res 41(11 Pt 1):4678–4686PubMed Brodeur GM, Green AA, Hayes FA et al (1981) Cytogenetic features of human neuroblastomas and cell lines. Cancer Res 41(11 Pt 1):4678–4686PubMed
34.
go back to reference Ishino S, Hashimoto N, Fushiki S et al (1998) Loss of material from chromosome arm 1p during malignant progression of meningioma revealed by fluorescent in situ hybridization. Cancer 83(2):360–366PubMedCrossRef Ishino S, Hashimoto N, Fushiki S et al (1998) Loss of material from chromosome arm 1p during malignant progression of meningioma revealed by fluorescent in situ hybridization. Cancer 83(2):360–366PubMedCrossRef
37.
go back to reference Barbashina V, Salazar P, Holland EC et al (2005) Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res 11(3):1119–1128. doi:11/3/1119 PubMed Barbashina V, Salazar P, Holland EC et al (2005) Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res 11(3):1119–1128. doi:11/​3/​1119 PubMed
Metadata
Title
Promoter hypermethylation-mediated down-regulation of RUNX3 gene in human brain tumors
Authors
C. B. Avci
Y. Dodurga
S. Y. Susluer
Z. O. D. Sıgva
M. Yucebas
H. O. Caglar
T. Akalin
T. Dalbasti
N. Oktar
C. Gunduz
Publication date
01-06-2014
Publisher
Springer London
Published in
Irish Journal of Medical Science (1971 -) / Issue 2/2014
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-013-1001-3

Other articles of this Issue 2/2014

Irish Journal of Medical Science (1971 -) 2/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.